CVKD vs PTGX vs IMVT vs ARDX vs JNJ

For growth investors, Ardelyx, Inc.

(ARDX) is the stronger pick with 22. 1% revenue growth year-over-year, versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). Johnson & Johnson (JNJ) offers the better valuation at 38. 2x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate Protagonist Therapeutics, Inc. (PTGX) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Johnson & Johnson is actually cheaper at 19.

1x.

Over the past 5 years, Ardelyx, Inc.

(ARDX) delivered a total return of +313. 4%, compared to -90. 1% for Cadrenal Therapeutics, Inc. Common Stock (CVKD). Over 10 years, the gap is even starker: PTGX returned +749. 2% versus CVKD's -90. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

04β versus Cadrenal Therapeutics, Inc. Common Stock's 2. 07β — meaning CVKD is approximately 4520% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 127% for Ardelyx, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ardelyx, Inc.

(ARDX) is pulling ahead at 22. 1% versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). On earnings-per-share growth, the picture is similar: Cadrenal Therapeutics, Inc. Common Stock grew EPS 23. 9% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Over a 3-year CAGR, ARDX leads at 98. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Johnson & Johnson (JNJ) is the more profitable company, earning 15.

8% net margin versus -282. 8% for Protagonist Therapeutics, Inc. — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus -343. 6% for PTGX. At the gross margin level — before operating expenses — PTGX leads at 97. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Johnson & Johnson (JNJ) trades at 19.

1x forward P/E versus 25. 8x for Protagonist Therapeutics, Inc. — 6. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARDX: 150. 7% to $17. 00.

In this comparison, JNJ (2.

2% yield) pays a dividend. CVKD, PTGX, IMVT, ARDX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), 2. 2% yield, +131. 3% 10Y return). Cadrenal Therapeutics, Inc. Common Stock (CVKD) carries a higher beta of 2. 07 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JNJ: +131. 3%, CVKD: -90. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CVKD is a small-cap quality compounder stock; PTGX is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; ARDX is a small-cap high-growth stock; JNJ is a large-cap quality compounder stock. JNJ pays a dividend while CVKD, PTGX, IMVT, ARDX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.